BAFF CAR-T Cells (LMY-922)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
What's the purpose of the trial?
This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against refractory hematologic malignancies using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.
Not yet accepting
Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- LMY-922
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Not yet accepting
Not yet accepting
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.